SMMTHealthcare · BiotechnologyThe 17 Wall Street analysts covering Summit Therapeutics, Inc. hold a median 12-month price target of $33 — +115.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 26 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Summit Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (22): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SMMT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +115.1% from it.
Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Barclays | Maintains | Equal-Weight | $18 → $20 |
| 29 Sept 2026 | Citigroup | Maintains | Buy | $40 → $43 |
| 23 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 23 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 Sept 2026 | Jefferies | Upgrade | Buy | $15 → $25 |
| 9 Sept 2026 | Jefferies | Upgrade | Buy | — |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 25 Aug 2026 | Bernstein | Upgrade | Market Perform | — |
| 25 Aug 2026 | Bernstein | Upgrade | Market Perform | $9.80 → $12 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Aug 2026 | Leerink Partners | Upgrade | Market Perform | $12 → $13 |
| 12 Aug 2026 | Leerink Partners | Upgrade | Market Perform | — |
| 24 July 2026 | Guggenheim | Maintains | Buy | — |
| 24 July 2026 | Guggenheim | Maintains | Buy | $40 → $38 |
| 24 July 2026 | Stifel | Maintains | Buy | — |
| 24 July 2026 | Stifel | Maintains | Buy | $45 → $38 |
| 23 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 23 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SMMT appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Summit Therapeutics, Inc. returned −21.2% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 5% of US stocks
Cheaper than 87% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 8% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Summit Therapeutics, Inc. has a market value of $12.3B and an enterprise value of $11.7B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$856.0M.
Diluted earnings per share, trailing twelve months: $−1.12.
Free cash flow in the twelve months to 30 June 2026: −$459.8M, after $1.4M of capital spending.
Trailing P/E: 25.0×; forward P/E: −13.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Summit Therapeutics, Inc. employs 265 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Summit Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MarketBeat says the S&P 500 remains in a confirmed uptrend, while market gains are concentrated in mega-cap leaders and many other companies trade below their 50-day moving averages despite resilient earnings outlooks.
Why it matters — The excerpt gives broader market context but does not mention Summit Therapeutics or any SMMT-specific catalyst.
Summit Therapeutics noted that its partner Akeso announced positive Phase III HARMONi-GI1 results in China. Ivonescimab plus chemotherapy demonstrated overall survival superiority over durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer.
Why it matters — The announcement concerns clinical results for ivonescimab, a potential first-in-class investigational bispecific antibody developed by SMMT partner Akeso.
Lunit and Summit Therapeutics announced a research agreement to evaluate Lunit’s AI-powered SCOPE IO pathology platform for tumor microenvironment analysis. The work will use H&E whole-slide images in support of Summit’s immuno-oncology development programs with ivonescimab.
Why it matters — The agreement adds an AI-based pathology analysis effort to Summit’s ivonescimab development programs.
Summit Therapeutics and Lunit announced a research agreement to evaluate Lunit’s AI-powered SCOPE IO pathology platform for tumor microenvironment analysis. The work will use H&E-stained whole-slide images to support Summit’s immuno-oncology development programs with ivonescimab.
Why it matters — The agreement concerns an AI-based approach to analyzing tumor samples in support of Summit’s ivonescimab development programs.
Summit Therapeutics is advancing ivonescimab into biliary tract cancer (BTC) with a Phase II/III study comparing its survival benefits with established immunotherapy regimens.
Why it matters — The study expands ivonescimab’s development into BTC, a new area for SMMT watchers to follow.
The 17 Wall Street analysts covering Summit Therapeutics, Inc. have a median 12-month price target of $33, with estimates ranging from $12 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Summit Therapeutics, Inc., 11 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Summit Therapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Summit Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +115.1% from the last close, and Ticker Nerd's factor model ranks Summit Therapeutics, Inc. 29 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Summit Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SMMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $44 over the next 12 months.
Summit Therapeutics, Inc. returned -21.2% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs.
The most recent item we track (MarketBeat, 26 Oct 2026): "Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts". MarketBeat says the S&P 500 remains in a confirmed uptrend, while market gains are concentrated in mega-cap leaders and many other companies trade below their 50-day moving averages despite resilient earnings outlooks.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.
CEO Mr. Robert W. Duggan · 265 employees · United States · https://www.smmttx.com
